Company profile: Oxford Immunotec
1.1 - Company Overview
Company description
- Provider of medical diagnostic tests based on patented T cell measurement technology, including T-SPOT.TB, an interferon gamma release assay for diagnosing latent TB infection and TB disease; T-SPOT.CMV for detecting cytomegalovirus infections; and T-SPOT.PRT for assessing immune responses to various pathogens.
Products and services
- T-SPOT.CMV: A patented T-cell measurement-based test that detects cytomegalovirus infection by measuring the immune response of T cells to CMV-specific antigens
- T-SPOT.PRT: A T-cell measurement-based test that assesses immune responses to various pathogens by measuring T cell activity
- T-SPOT.TB: An IGRA-based diagnostic that measures T-cell responses to TB-specific antigens to diagnose latent TB infection (LTBI) and TB disease
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Oxford Immunotec
Advitos
HQ: Germany
Website
- Description: Provider of the CE-marked, globally patented ADVOS technology based on albumin dialysis—the first multi-organ support method for liver, lung, kidney, and acid-base balance. The ADVOS System enables extracorporeal elimination of CO2, hepatic toxins, water-soluble and protein-bound nephrotoxins, and correction of metabolic and respiratory acidosis. Offers ADVOS Workshops for hands-on training and ADVOS User Meetings for knowledge exchange.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Advitos company profile →
OrganOx
HQ: United Kingdom
Website
- Description: Provider of normothermic machine perfusion technology for donor livers via OrganOx metra, enabling functional assessment and preservation for up to 24 hours. Offerings support evaluation of liver function prior to transplantation, provide more flexible transplant logistics and surgery scheduling, and support complex or lengthy surgeries by extending preservation time.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full OrganOx company profile →
XVIVO Perfusion
HQ: Sweden
Website
- Description: Provider of medical technology solutions for organ, tissue, and cell preservation in transplantation, offering the XPS ex‑vivo lung perfusion system, Kidney Assist Transport for hypothermic pulsatile perfusion, Liver Assist protocols, PERFADEX Plus lung preservation solution, and the XVIVO Academy to improve transplant outcomes and support transplant teams.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full XVIVO Perfusion company profile →
Vascular Perfusion Solutions
HQ: United States
Website
- Description: Provider of medical devices to preserve and resuscitate vascularized organs, notably the VP.S ENCORE hypothermic machine perfusion system that extends organ viability for transplantation using a nutrient-rich solution instead of ice. Compact and carry-on sized, it includes a single-use component, operates in various environments, and enables reliable organ transport by ground or aircraft without special vehicles.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Vascular Perfusion Solutions company profile →
Verici Dx
HQ: United States
Website
- Description: Provider of RNA signature-based diagnostics for kidney transplant patients, offering pre- and post-transplant prognostic tests—Clarava to predict early rejection risk and Tutivia to assess post-transplant rejection risk—and RNA Signature Tests that provide insights into immune response and transplant prognosis, while tracking patient records and the patient journey.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Verici Dx company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Oxford Immunotec
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Oxford Immunotec
2.2 - Growth funds investing in similar companies to Oxford Immunotec
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Oxford Immunotec
4.2 - Public trading comparable groups for Oxford Immunotec
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →